Excellent piece Kashish. Wouldn't the Chinese be very strong competitors for the export markets? And don't they sell the Srmaglutide API to a number of India pharma companies ?
Both fair points. Yes — China is the real competition in the export markets, especially the semi-regulated ones where they can come in cheap on the API and squeeze the margin in the bull case. India's edge is mostly in the highly regulated markets (US, Canada, EU), where the quality bar is high and the likes of Dr Reddy's and Biocon have a head start — which is partly why Dr Reddy's just landed the first Canada approval.
And you're right that a lot of Indian launchers buy their semaglutide API rather than make it, and China's a big source. That's exactly why the vertically integrated players — Biocon with its fermentation cost edge, Divi's making its own amino acids — stand apart from the ones just marketing someone else's molecule
Actually a good article explaining the current dynamics in indian pharna
Good overview and classification of the landscape. You have however missed out on Shaily Engineering which makes pens
Yes, that's a miss from our end completely. Thanks for pointing it out!
Excellent piece Kashish. Wouldn't the Chinese be very strong competitors for the export markets? And don't they sell the Srmaglutide API to a number of India pharma companies ?
Thanks Ketan :)
Both fair points. Yes — China is the real competition in the export markets, especially the semi-regulated ones where they can come in cheap on the API and squeeze the margin in the bull case. India's edge is mostly in the highly regulated markets (US, Canada, EU), where the quality bar is high and the likes of Dr Reddy's and Biocon have a head start — which is partly why Dr Reddy's just landed the first Canada approval.
And you're right that a lot of Indian launchers buy their semaglutide API rather than make it, and China's a big source. That's exactly why the vertically integrated players — Biocon with its fermentation cost edge, Divi's making its own amino acids — stand apart from the ones just marketing someone else's molecule